Chiu Alexander, Chan Lina Mun Yee, Fan Sheung Tat
Intensive Care Unit, Queen Mary Hospital, Hong Kong, China.
Liver Int. 2006 Aug;26(6):695-702. doi: 10.1111/j.1478-3231.2006.01293.x.
The molecular adsorbent recirculating system (MARS) is an extracorporeal liver dialysis system that allows selective removal of bilirubin and other albumin-bound toxins. We reported here our experience with the use of this technique for management of liver failure at Queen Mary Hospital, Hong Kong.
From December 2002 to 2004, a total of 74 MARS sessions were performed on 22 patients. The cause of liver failure included acute liver failure (n = 2), acute on chronic liver failure (n = 12), posthepatectomy liver failure (n = 4), and posttransplantation allograft failure (n = 4).
MARS treatment showed significant reduction in total bilirubin level, serum ammonia level and blood urea, and nitrogen (P < 0.001 for all three parameters). Five patients (22.7%) were able to bridge to transplantation and one patient (4.5%) made a spontaneous recovery. The 30-day mortality rate was 72.7%.
Our results indicated that MARS can effectively improve serum biochemistry and is suitable for temporarily supporting patients with liver failure where transplantation is not immediately available. There is, however, no clear evidence showing that MARS can increase survival, improve the chance of transplantation or assist liver regeneration. Future studies in the form of randomized-controlled trials are crucial to characterize the true potential of this treatment.
分子吸附再循环系统(MARS)是一种体外肝脏透析系统,可选择性清除胆红素及其他与白蛋白结合的毒素。我们在此报告了香港玛丽医院使用该技术治疗肝衰竭的经验。
2002年12月至2004年,共对22例患者进行了74次MARS治疗。肝衰竭的病因包括急性肝衰竭(2例)、慢性肝衰竭急性发作(12例)、肝切除术后肝衰竭(4例)和移植后移植物衰竭(4例)。
MARS治疗使总胆红素水平、血清氨水平和血尿素氮显著降低(所有三个参数P均<0.001)。5例患者(22.7%)成功过渡到肝移植,1例患者(4.5%)自发康复。30天死亡率为72.7%。
我们的结果表明,MARS可有效改善血清生化指标,适用于在无法立即进行肝移植时临时支持肝衰竭患者。然而,尚无明确证据表明MARS可提高生存率、增加肝移植机会或促进肝脏再生。未来以随机对照试验形式开展的研究对于明确该治疗的真正潜力至关重要。